SCHEMBL5030896

SCHEMBL5030896

CNCCNC(=O)CCC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 6/20 0.54
KDM2A Q9Y2K7 6/20 0.54
KDM4E B2RXH2 4/20 0.54
KDM5C P41229 4/20 0.54
EGLN1 Q9GZT9 4/20 0.54
KDM6B O15054 2/20 0.48
FOLH1 Q04609 1/20 0.48
KDM7A Q6ZMT4 1/20 0.46
ALDH1A1 P00352 2/20 0.45
ECE1 P42892 1/20 0.45
LMNA P02545 2/20 0.43
ALKBH5 Q6P6C2 1/20 0.43
SUCNR1 Q9BXA5 1/20 0.43
KMT2A Q03164 1/20 0.41
NAAA Q02083 1/20 0.41
SLC15A2 Q16348 1/20 0.40
HTT P42858 1/20 0.40
EPHX2 P34913 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6810784 0.87 PHF8 (0.60) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL15080736 0.87 CASP2 (0.52) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL17278230 0.87 EPHX2 (0.54) KDM4EALDH1A1LMNAKMT2AEPHX2
SCHEMBL16281002 0.86 ALDH1A1 (0.45) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL14002750 0.85 ALDH1A1 (0.48) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL12251401 0.84 PHF8 (0.44) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL19115845 0.84 ALDH1A1 (0.46) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL16687527 0.83 ECE1 (0.41) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL1387345 0.83 NAAA (0.57) ALDH1A1KMT2ANAAA
SCHEMBL13839061 0.83 FAAH (0.50) ALDH1A1KMT2ANAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054981-B1 PROTECTING GROUP COMPRISING A PURIFICATION TAG ASCENDIS PHARMA AS (DK) 2020-07-29 EP disclosed
US-9321781-B2 Topoisomerase inhibitors RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-04-26 US disclosed
EP-1984726-B1 METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION DH TECHNOLOGIES DEV PTE LTD (SG) 2015-06-17 EP disclosed
US-8975404-B2 Labeling reagents for analyte determination and methods and compounds used in making the same DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) 2015-03-10 US disclosed
US-20120237531-A1 TOPOISOMERASE INHIBITORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2012-09-20 US disclosed
WO-2010127363-A1 TOPOSIOMERASE INHIBITORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2010-11-04 WO disclosed
EP-1984726-A2 METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION Applera Corporation (US) 2008-10-29 EP disclosed
US-20070218560-A1 Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination APPLERA CORPORATION. (US) 2007-09-20 US disclosed
WO-2007087534-A2 METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION APPLERA CORPORATION (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070218560-A1 Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination SRMS, CA13, KLK3 PHF8 3012/4885KDM2A 3327/4885KDM4E 3535/4885
US-20120237531-A1 TOPOISOMERASE INHIBITORS TOP1, TOP2A, TOP2B PHF8 1259/4885KDM2A 786/4885KDM4E 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.